Advertisement
Singapore markets close in 3 hours 58 minutes

  • Straits Times Index

    3,269.57
    -30.47 (-0.92%)
     

  • Nikkei

    38,230.13
    -604.97 (-1.56%)
     

  • Hang Seng

    18,410.20
    -69.17 (-0.37%)
     

  • FTSE 100

    8,313.67
    +100.18 (+1.22%)
     

  • Bitcoin USD

    62,504.69
    -928.59 (-1.46%)
     

  • CMC Crypto 200

    1,296.25
    -68.87 (-5.05%)
     

  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     

  • Dow

    38,884.26
    +31.99 (+0.08%)
     

  • Nasdaq

    16,332.56
    -16.69 (-0.10%)
     

  • Gold

    2,326.30
    +2.10 (+0.09%)
     

  • Crude Oil

    78.00
    -0.38 (-0.48%)
     

  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     

  • FTSE Bursa Malaysia

    1,605.33
    -0.35 (-0.02%)
     

  • Jakarta Composite Index

    7,096.12
    -27.49 (-0.39%)
     

  • PSE Index

    6,597.68
    -20.90 (-0.32%)
     

Moderna, BioNTech Plunge As EU Studies Possible Side-effects Of mRNA Shots

Investing.com
·1-min read

By Dhirendra Tripathi

Investing.com – Moderna (NASDAQ:MRNA) and BioNTech stocks (NASDAQ:BNTX) slumped by 15% each Wednesday on a report that Europe’s drug regulator is studying three new conditions reported by a small number of people after vaccination with Covid-19 shots to assess if they may be possible side-effects.

The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.

Pfizer stock fell 3%. Expenses and profit from the Covid vaccine are split equally between Pfizer (NYSE:PFE) and BioNTech.

BioNTech-Pfizer is the biggest supplier of Covid-19 vaccines to Europe.

ADVERTISEMENT

Just over 43.5 million doses of Moderna's vaccine have been administered in the European Economic Area as of July 29, the EMA said, compared to more than 330 million doses of the BioNTech-Pfizer shot.

Related Articles

Moderna, BioNTech Plunge As EU Studies Possible Side-effects Of mRNA Shots

2 SaaS Stocks Worth Holding for the Long Haul

Cohu vs. ACM Research: Which Semiconductor Equipment & Materials Stock is a Better Buy?